ADVERTISEMENT
MDD Symptom Improvements With Zuranolone Extend to Daily Lives, Responders Report
Patients with major depressive disorder (MDD) who responded to treatment with zuranolone said they experienced rapid improvement in depressive symptoms as well as improvements in their daily lives, according to a poster presentation at Psych Congress in Nashville, Tennessee, in September.
Zuranolone is a once-daily, 14-day oral treatment in clinical development for adults with MDD. The US Food and Drug Administration recently approved the medication to treat adults with postpartum depression.
To gain insight into patient experiences with zuranolone, researchers interviewed a convenience sample consisting of 32 adults with MDD who showed a clinical response to 50-mg once-daily zuranolone in an ongoing open-label study called SHORELINE. The average age of participants was 40.6 years, and just over half were male.
All patients interviewed reported improvement in one or more MDD symptoms with zuranolone, according to the poster abstract. Some 87.5% noticed improvements within the first week of treatment.
NEWS>>Novel Esketamine Treatment Shows Promise in Managing Fluctuating Antidepressant Response
Before receiving zuranolone, 27 patients experienced adverse MDD-related symptoms affecting their social lives, activities, or relationships, the study found. Following treatment, they all reported improvement in those areas.
“All participants agreed seeing improvements within a short time period was meaningful to them,” wrote first author Amanda McDaniel, PMHNP-BC, of the Caprock Alliance For Mental Wellness, and coauthors. “Of the 29 patients who described what they most liked about zuranolone, many liked that it helped manage their depression or another specific MDD-related symptom and the 14-day treatment course.”
Sage Therapeutics Inc. and Biogen Inc. sponsored the study.
References
McDaniel A, et al. Understanding the experiences of patients with major depressive disorder treated with zuranolone: qualitative interviews with participants from the open-label SHORELINE study. Poster presented at Psych Congress; September 6-10, 2023; Nashville, Tennessee.
